Department of Neurosciences DNS, University of Padova, via Giustiniani, 5, 35128, Padua, Italy.
Scientific Institute IRCCS E. Medea, NeuroMuscular Unit, Lecco, Bosisio Parini, Italy.
J Neurol. 2022 Sep;269(9):4884-4894. doi: 10.1007/s00415-022-11133-8. Epub 2022 May 5.
Genetic modifiers of Duchenne muscular dystrophy (DMD) are variants located in genes different from the disease-causing gene DMD, but associated with differences in disease onset, progression, or response to treatment. Modifiers described so far have been tested mainly for associations with ambulatory function, while their effect on upper limb function, which is especially relevant for quality of life and independence in non-ambulatory patients, is unknown. We tested genotypes at several known modifier loci (SPP1, LTBP4, CD40, ACTN3) for association with Performance Upper Limb version 1.2 score in an Italian multicenter cohort, and with Brooke scale score in the Cooperative International Neuromuscular Group Duchenne Natural History Study (CINRG-DNHS), using generalized estimating equation (GEE) models of longitudinally collected data, with age and glucocorticoid treatment as covariates. CD40 rs1883832, previously linked to earlier loss of ambulation, emerged as a modifier of upper limb function, negatively affecting shoulder and distal domains of PUL (p = 0.023 and 0.018, respectively) in the Italian cohort, as well as of Brooke score (p = 0.018) in the CINRG-DNHS. These findings will be useful for the design and interpretation of clinical trials in DMD, especially for non-ambulatory populations.
Duchenne 肌营养不良症 (DMD) 的遗传修饰因子是位于与致病基因 DMD 不同的基因中的变异体,但与疾病发作、进展或治疗反应的差异有关。到目前为止,已经描述的修饰因子主要用于与非卧床患者的生活质量和独立性特别相关的运动功能相关的关联研究,而它们对上肢功能的影响则未知。我们使用纵向收集数据的广义估计方程 (GEE) 模型,以年龄和糖皮质激素治疗为协变量,在意大利多中心队列中,对几个已知的修饰因子 (SPP1、LTBP4、CD40、ACTN3) 的基因型与 Performance Upper Limb version 1.2 评分进行关联分析,并在 Cooperative International Neuromuscular Group Duchenne Natural History Study (CINRG-DNHS) 中,与 Brooke 量表评分进行关联分析。先前与运动功能丧失较早相关的 CD40 rs1883832 被确定为上肢功能的修饰因子,在意大利队列中,它对 PUL 的肩部和远端域有负面影响(p=0.023 和 0.018),在 CINRG-DNHS 中,对 Brooke 评分也有负面影响(p=0.018)。这些发现将有助于设计和解释 DMD 的临床试验,尤其是对非卧床人群的临床试验。